In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy for Non-Hodgkin lymphoma (NHL).

Researchers can manipulate genomes at the single-base level, but they still struggle to predict and detect the editing outcomes precisely. Eric Paul...

We have added 6 new cancer trials to our overview of current clinical trials involving gene editing.